Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial ...

ARTESiA (Apixaban for the Reduction of Thrombo-Embolism in Patients with Device-Detected Sub-Clinical Atrial Fibrillation) ...

apixaban and warfarin, to prevent stroke in patients with non-valvular atrial fibrillation. The study provides a method to explore the effects of treatments in patients who are underrepresented or ...

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a ...

apixaban and warfarin, to prevent stroke in patients with non-valvular atrial fibrillation. The study, led by Emma Maud Powell at the London School of Hygiene and Tropical Medicine, UK ...

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the ...

London, United Kingdom – 1 September 2024: Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF ...

we randomly assigned high-risk patients with atrial fibrillation in a 1:1 ratio to receive asundexian at a dose of 50 mg once daily or standard-dose apixaban. The primary efficacy objective was to ...

In the OCEANIC-AF trial, asundexian was found to be inferior to apixaban for stroke prevention in patients with a high risk ...

Atrial fibrillation (AF) is the most common cardiac ... Novel anticoagulants include dabigatran, rivaroxaban and apixaban. Based on the RE-LY study, a 150-mg dose of dabigatran as compared with ...